Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency
use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) …

With the recent spread of severe acute respiratory syndrome coronavirus (SARS-CoV-2) _
infecting> 16 million people worldwide as of 28 July 2020, causing> 650 000 deaths, there …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

As the coronavirus disease 2019 (COVID-19) pandemic continues, there is a strong need for
highly potent monoclonal antibodies (mAbs) that are resistant against severe acute …

Neutralizing antibodies for the treatment of COVID-19 | Nature Biomedical Engineering Skip to
main content Thank you for visiting nature.com. You are using a browser version with limited …

With the number of Coronavirus Disease 2019 (COVID-19) cases soaring worldwide and
limited vaccine availability for the general population in most countries, the monoclonal …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
have become a major concern in the containment of current pandemic. The variants …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

Antibody-dependent enhancement (ADE) of disease is a general concern for the
development of vaccines and antibody therapies because the mechanisms that underlie …